Article Information
PubMed
Print ISSN
Online ISSN
History
- Received July 21, 2011
- Accepted September 14, 2011
- Published online November 21, 2011.
Article Versions
- Earlier version (September 14, 2011 - 09:53).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Megumi Iwai,
- Tsuyoshi Minematsu,
- Qun Li,
- Takafumi Iwatsubo and
- Takashi Usui
- Drug Metabolism Research Laboratories, Astellas Pharma Inc., Osaka, Japan (M.I., T.M., T.I., T.U.); and Translational and Development Pharmacology, Applied Pharmacology Research Laboratories, Astellas Pharma Europe BV, Leiderdorp, The Netherlands (Q.L.)
- Address correspondence to:
Megumi Iwai, Drug Metabolism Research Laboratories, Astellas Pharma Inc., 2-1-6, Kashima, Yodogawa-ku, Osaka, Japan. E-mail: megumi.iwai{at}astellas.com
Part of this work were previously presented as follows: Iwai M, Minematsu T, Li Q, Iwatsubo T, and Usui T (2010) Involvement of multidrug resistance1 (MDR1) for the pharmacokinetics of YM155, a novel survivin suppressant. 9th International ISSX Meeting; 2010 Sept 4–8; Istanbul, Turkey. International Society for the Study of Xenobiotics, Washington, DC.
Statistics from Altmetric.com
Article usage
In this issue
INTERACTION OF YM155 WITH P-GLYCOPROTEIN
